Introduction: Streptococcus pneumoniae is a major Gram-positive pathogen responsible for pneumonia, bactermia, otitis media, and meningitis leading to considerable morbidity and mortality among children and elderly individuals. The primary goals of antibiotic treatment of respiratory tract infections are clinical efficacy of treatment, pathogen eradication, and prevention of resistance development. Resistance to fluoroquinolones in S. pneumoniae arises in a stepwise fashion and results from alterations in the target binding site due to the acquisition of spontaneous mutations in the quinolone resistance-determining regions (QRDRs) of the topoisomerase IV and DNA gyrase genes. Although mutations usually occur in the QRDRs of parC and gyrA, a role for mutations in the parE subunit in low-level resistance has been reported. Aim of the work: The aim of this study was to determine the prevalence of fluoroquinolone resistance Streptococcus pneumoniae (FQRSP) and to examine the genetic relatedness of pneumococcal isolates with parE and gyrA genes mutations in different specimens in Sohag University Hospital. Patients and Methods: This study was prospectively conducted over a period of 24 months between October 2015 and September 2017, at Sohag university hospital. During the study period, 78 patients hospitalized for a syndrome consistent with a diagnosis of community acquired pneumonia (CAP ) included in this study with a mean age of 34.5 years (range, 2 to 67), 60% of whom were males. A CAP syndrome was defined as a newly recognized pulmonary infiltrate together with 2 of the following findings: subjective fever or documented temperature 37.4 °C, increased cough, sputum production, or shortness of breath, pleuritic chest pain, confusion, rales, leukocytosis, (according to age) (1) . Patients who had taken antibiotic treatment within 3 days prior to initial visit were excluded from this study. Results: Our study illustrate the role of mutation in the gyrA&parE genes and the effect of mutations in the both genes in fluoroquinolone resistance among S. pneumoniae isolates.
Introduction
Streptococcus pneumoniae is a major Gram-positive pathogen responsible for pneumonia, bactermia, otitis media, and meningitis leading to considerable morbidity and mortality among children and elderly individuals. The primary goals of antibiotic treatment of respiratory tract infections are clinical efficacy of treatment, pathogen eradication, and prevention ofresistance development. Penicillin, a β-lactam antibiotic, has long been the mainstay against pneumococcal infections, but the worldwide spread of antibioticresistant clones over the past decades has impaired its usefulness for dealing with S. pneumoniae infections. pneumoniae remains low in relation to β-lactam resistance (<1%), the dissemination of successful resistant clones has nonetheless increased the prevalence in some countries (4) . Resistance to fluoroquinolones in S. pneumoniae arises in a stepwise fashion and results from alterations in the target binding site due to the acquisition of spontaneous mutations in the quinolone resistance-determining regions (QRDRs) of the topoisomerase IV and DNA gyrase genes. Although mutations usually occur in the QRDRs of parE and gyrA, a role for mutations in the parE and gyrAsubunits in low-level resistance has been reported (5) . Inappropriate use of any antibiotic can contribute to the emergence of resistance to that and related agents. So much work is needed to identify optimal strategies to prevent the emergence and spread of resistant pneumococcal strains in long-term care facilities, including potential use of pneumococcal conjugate vaccines, antimicrobial stewardship, and infection control interventions to interrupt transmission (6) .
Aim of the work
The aim of this study was to determine the prevalence of fluoroquinolone resistance Streptococcus pneumoniae (FQRSP) and to examine the genetic relatedness of pneumococcal isolates with parE and gyrA genes mutations in different specimens.
Patients and Methods:
Patients: This study was prospectively conducted over a period of 24 months between October 2015 and September 2017, at Sohag university hospital. During the study period, 78 patients hospitalized for a syndrome consistent with a diagnosis of CAP included in this study with a mean age of 34.5 years (range, 2 to 67), 60% of whom were males.
A CAP syndrome was defined as a newly recognized pulmonary infiltrate together with 2 of the following findings: subjective fever or documented temperature 37.4 °C, increased cough, sputum production, or shortness of breath, pleuritic chest pain, confusion, rales, leukocytosis, (according to age) (1) . Patients who had taken antibiotic treatment within 3 days prior to initial visit were excluded from thisstudy.
Methods

Specific investigations
Clinical specimens and clinical laboratory work. Fresh sputum samples were collected soon after collection of data from patients (75 specimens). Representative sputum originating from the lower respiratory tract was defined as that containing > 25 granulocytes and < 10 epithelial cells per low power field (lpf: total magnification:×100) (1 Before starting: 26 ml 95% ethanol was added to the 6 ml DNA Wash Buffer concentrate. Protocol:-(according to manufacture instruction) 1-The DNA bands were exiced from the agarose gel with a sterile razor plate and placed in a 1.5 ml microcentrifuge tube, 5 volumes of DNA Binding Buffer were added to each volume of DNA samples placed at 50 °C for 10 minutes . Then mixed by pulsevortexing for 15 seconds every 2-3 minutes till the agarose completely dissolved. 2-Then the DNA (including the precipitate) was carefully added to a provided Zymo-Spin™ Column in a 2 ml Collection Tube without wetting the rim. Then the cap was closed to avoid aerosol formation duringcentrifugation. 3-The DNA was centrifuged at 14000 rpm for 30 seconds. Then the ZymoSpin™ Column was placed in a clean 2 ml collection tube and the tube contating the filterate wasdiscarded. 4-200 ul DNA Wash Buffer was added to the column without wettingthe added directly to the column matrix without wetting the rim and incubate at room temperature for one minute. The Zymo-Spin™ Column was placed in a clean 1.5 ml microcentrifuge tube then centrifuged at 14000 rpm for 30 seconds to elute theDNA. Ultra-Pure DNA was ready to use for the next sequencing step.
ii) DNAsequencing
Sequencing 
Results
During the period from October 2015 and September 2017 our study was carried out in the Clinical Pathology Department, faculty of medicine, Sohag University Hospital, 78 participants included in our study, the majority of the isolates were isolated from males, 49 (62.8%) male and 29 (37.2%) female, aged ranged from 1 to 64 years with mean age 22.2±20.8. Inflammatory biomarkers differentiating viral from bacterial infections have been evaluated in our study to support clinical diagnosis. The majority of our study group had high ESR values 65 (83.3%), and positive CRP 64 (82.1%). Also in our study, it was observed that WBCs was high in 63/78 (82.1%) of cases. S. pneumoniae was isolated from 78 patients included in this study. The resistance percentages of all strains to tested antibiotics were as follows: 91% of isolates in our study were resistant to Ampicillin, 5.1% were intermediate and 3.8% were susceptible. Regarding Cefaclor 83.3% were resistant, 7.7% were intermediate and 9% were susceptible. Erythromycin was resistant in 82.1% of isolates, intermediate in 10.3%, and susceptible in 7.7%. Regarding Imipenem 10.3% of isolates were resistant. Tetracycline was resistant in 71.8% of isolates. Clarithromycin was resistant in only 6.4%, also 10.3% of our isolates were resistant to ceftriaxone. Trimethoprim/ sulfamethoxazole was resistant in 9% of ourisolates. (Table 1) (12) , Broskey et al. (13) , Brueggemann et al. (14) the GyrA substitutions observed most often were at positions Ser81 (Phe or Tyr) (54% of ciprofloxacin-resistant isolates) and Glu85 (Gly or Lys) (10% of ciprofloxacin-resistant is olates). Overall, the most common genotype observed was Ser79Phe (ParC) and Ser81Phe (GyrA) (35% of ciprofloxacinresistant isolates). Also in study of Korzheva et al. 
Break points of antibiotics
"Ampicillin" ≥ 2 R & 0.12 -1 I & ≤ 0.06 S , "Cefaclor" > 16 R & 8 -16 I & ≤ 4 S, "Erythromycin" ≥ 1 R & 0.5 I & ≤ 0.25 S, "Imipenem" ≥ 1 R & 0.5 I & ≤ 0.25 S "Tetracyclin" ≥ 8 R & 4 I & ≤ 2 S, "Clarithromycin" ≥ 2 R & 1 I & ≤ 0.5 S, "Ceftriaxone" ≥ 2 R & 1 I & ≤ 0.5 S and "Trimethoprim-Sulfamethaxzole " ≥ 4 R & 1 -2 I & ≤ 0.5S.
Conclusion
There is a strong relationship between these mutations and decrese susceptibility to the most fameous FQs to some extent, 
Recommandations
